OCGNOcugen, Inc.

Nasdaq ocugen.com


$ 1.21 $ 0.01 (0.83 %)    

Friday, 13-Sep-2024 15:59:57 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 1.21
$ 1.21
$ 1.20 x 3,422
-- x --
$ 1.18 - $ 1.23
$ 0.35 - $ 2.11
3,556,248
na
348.31M
$ 1.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 04-16-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-21-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-05-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-19-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-27-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 03-22-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-15-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-10-2017 06-30-2017 10-Q
30 05-11-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-10-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-27-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ocugen-receives-green-light-from-health-canada-for-phase-3-trial-of-gene-therapy-for-retinitis-pigmentosa

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, develop...

 why-ocugen-ocgn-stock-is-falling

Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering.

 ocugen-announces-underwritten-public-offering-of-common-stock-size-not-disclosed

Grants Underwriter 30-Day Option To Purchase Additional 15% Shares; Offering Subject To Market And Other Conditions

 ocugen-discloses-data-and-safety-monitoring-board-approves-enrollment-in-high-dose-cohort-3-in-gardian-study-for-stargardt-disease-company-says-it-established-medium-dose-as-safe-and-tolerable-dose-in-current-ocu410st-clinical-trial

Six patients with Stargardt disease have been dosed in the Phase 1/2 clinical trial to date in the low dose cohort and medium d...

 ocugen-begins-phase-3-trial-for-gene-therapy-to-treat-retinitis-pigmentosa

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, develop...

 chardan-capital-maintains-buy-on-ocugen-maintains-5-price-target

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $5 price target.

 hc-wainwright--co-reiterates-buy-on-ocugen-maintains-7-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION